ASH 2018 - Passamonti

Francesco Passamonti, MD
Dipartimento di Medicina e Chirurgia, Università dell'Insubria, Varese, Italy

 

Ruxolitinib for the Treatment of Inadequately Controlled Polycythemia Vera without Splenomegaly: 156-Week Follow-up from the Phase 3 Response-2 Study

 

https://ash.confex.com/ash/2018/webprogram/Paper115350.html

 

0119JAK1106215
×

Ask Speakers

×

Medical Information Request